CELC
- Celcuity Inc.
()
Overview
Company Summary
Celcuity Inc. (CELC) is a biotechnology company that specializes in developing and commercializing personalized medicine and diagnostic tests. The company focuses on identifying and targeting new cancer subtypes using its proprietary CELsignia diagnostic platform.
Celcuity utilizes advanced cellular analysis technology to analyze the signaling networks within cancer cells. By examining the way these cells communicate and interact with each other, Celcuity aims to identify unique cell signaling patterns associated with different subtypes of cancer. This allows them to classify patients into specific subgroups and design personalized treatment plans.
One of the key products offered by Celcuity is the CELsignia HER2 test. This test is designed to identify patients with HER2-negative breast cancer who may still benefit from targeted therapy aimed at HER2-positive breast cancer. The CELsignia HER2 test helps doctors make more informed treatment decisions by identifying patients who may benefit from HER2-targeted treatments.
Celcuity is also working on expanding its diagnostic platform to address other types of cancers, such as those related to lung, colon, and ovarian tissues. By continuing to identify and validate new biomarkers and signaling networks, Celcuity aims to develop additional diagnostic tests that can improve patient outcomes and enable precision medicine approaches.
In summary, Celcuity Inc. is a biotechnology company that develops and commercializes personalized medicine and diagnostic tests. By analyzing cellular signaling networks, Celcuity aims to identify unique cancer subtypes and provide targeted treatment options for patients, with a particular focus on breast cancer and expanding into other cancer types.